Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients

Attila Kónyi, Zsolt Sárszegi, G. Hild, B. Gaszner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin. Patients & methods: Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol. Results: At 6 months, 91% of 2241 evaluable patients achieved blood pressure target (

Original languageEnglish
Pages (from-to)355-364
Number of pages10
JournalJournal of Comparative Effectiveness Research
Volume5
Issue number4
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Antihypertensive Agents
Lisinopril
Amlodipine
Cholesterol
Blood Pressure
Safety
Hypercholesterolemia
LDL Cholesterol
Therapeutics
Hypertension
Rosuvastatin Calcium

Keywords

  • cardiovascular risk
  • diabetes mellitus
  • hypercholesterolemia
  • hypertension
  • lisinopril-amlodipine
  • rosuvastatin

ASJC Scopus subject areas

  • Health Policy

Cite this

Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. / Kónyi, Attila; Sárszegi, Zsolt; Hild, G.; Gaszner, B.

In: Journal of Comparative Effectiveness Research, Vol. 5, No. 4, 01.07.2016, p. 355-364.

Research output: Contribution to journalArticle

@article{38560e33d48a44489cb2226b32d3b6d8,
title = "Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients",
abstract = "Aim: Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin. Patients & methods: Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol. Results: At 6 months, 91{\%} of 2241 evaluable patients achieved blood pressure target (",
keywords = "cardiovascular risk, diabetes mellitus, hypercholesterolemia, hypertension, lisinopril-amlodipine, rosuvastatin",
author = "Attila K{\'o}nyi and Zsolt S{\'a}rszegi and G. Hild and B. Gaszner",
year = "2016",
month = "7",
day = "1",
doi = "10.2217/cer-2016-0003",
language = "English",
volume = "5",
pages = "355--364",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients

AU - Kónyi, Attila

AU - Sárszegi, Zsolt

AU - Hild, G.

AU - Gaszner, B.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Aim: Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin. Patients & methods: Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol. Results: At 6 months, 91% of 2241 evaluable patients achieved blood pressure target (

AB - Aim: Controlling cardiovascular (CV) risk factors is paramount in reducing atherosclerotic events. This 6-month prospective noninterventional trial assessed the safety and effectiveness of fixed-combination lisinopril-amlodipine plus rosuvastatin. Patients & methods: Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day). Primary end points: systolic/diastolic blood pressure, low-density lipoprotein cholesterol. Results: At 6 months, 91% of 2241 evaluable patients achieved blood pressure target (

KW - cardiovascular risk

KW - diabetes mellitus

KW - hypercholesterolemia

KW - hypertension

KW - lisinopril-amlodipine

KW - rosuvastatin

UR - http://www.scopus.com/inward/record.url?scp=84978052624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978052624&partnerID=8YFLogxK

U2 - 10.2217/cer-2016-0003

DO - 10.2217/cer-2016-0003

M3 - Article

VL - 5

SP - 355

EP - 364

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 4

ER -